Provided by Tiger Trade Technology Pte. Ltd.

Incyte

126.01
+1.611.29%
Volume:1.30M
Turnover:164.16M
Market Cap:25.54B
PE:16.05
High:127.72
Open:125.66
Low:123.57
Close:124.40
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.96
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:4.03
PE(LYR):19.66

Loading ...

Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating

MT Newswires Live
·
Aug 03

Incyte Price Target Maintained with a $150.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 03

Incyte price target raised to $155 from $131 at Leerink

TIPRANKS
·
Aug 03

Incyte : Leerink Partners Raises Target Price to $155 from $131

THOMSON REUTERS
·
Aug 03

Incyte Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 01

Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating

MT Newswires Live
·
Jul 31

Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.
·
Jul 31

JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating

MT Newswires Live
·
Jul 30

Amneal Q2 Revenue Beats on Specialty Segment Growth

Reuters
·
Jul 30

Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 30

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Reuters
·
Jul 30

Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says

MT Newswires Live
·
Jul 30

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Benzinga Earnings
·
Jul 29

Incyte Says Opzelura Cream Approved in EU to Treat Moderate Atopic Dermatitis

MT Newswires Live
·
Jul 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)

TIPRANKS
·
Jul 29

Incyte is Maintained at Overweight by Barclays

Dow Jones
·
Jul 29

Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte : Morgan Stanley Raises Target Price to $119 from $104

THOMSON REUTERS
·
Jul 29

RBC Capital Sticks to Their Hold Rating for Incyte (INCY)

TIPRANKS
·
Jul 29

Incyte price target raised to $119 from $104 at Morgan Stanley

TIPRANKS
·
Jul 29